Creating a new class of implantable drug delivery technology

Advanced Chemotherapies Technologies, Inc. is a privately owned, clinical-stage company developing novel approaches to local drug delivery. 


Our lead product, ACT-IOP-003, is the first-in-class to combine iontophoresis drug delivery with an implantable delivery system to target drug delivery with laser-like precision. 


Advanced Chemotherapy Technologies drug delivery technology was first developed at and licensed from the University of North Carolina at Chapel Hill in conjunction with UNC Lineberger Comprehensive Cancer Center.


Advanced Chemotherapy Technologies has received funding from the U.S. National Institutes of Health (NIH) through SBIR awards, the North Carolina Biotechnology Center through strategic loans, and prior rounds of seed financing in 2017. The initial development and preclinical studies of the technology, which took place at the University of North Carolina, were funded through grants from the University Cancer Research Fund, the NIH, and the NIH Director’s Pioneer Award Program.

Leadership

Anthony Voiers

CEO

William Daunch, PhD

CTO

Board of Directors

Anthony Voiers

Chairman

Joseph DeSimone, PhD

Founder, Board Member

Jen Jen Yeh, MD

Founder, Board Member

Scientific & Medical Advisors

James Byrne MD, PhD

Richard Goldberg, MD

Cristina Ferrone, MD

Steve Schultz, MBA

Advanced Chemotherapy Technologies, Inc.

2301 Stonehenge Drive, Suite 204

Raleigh North Carolina 27615-4379

|   Contact  |   Privacy Policy   |   Terms and Conditions   |

Copyright © 2017-2020 Advanced Chemotherapy Technologies, Inc.  All Rights Reserved

This website makes use of cookies. Please see our privacy policy for details.

OK